塞拉斯生命科学

最新新闻

• 评级变动
  Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $10
  \u5e02\u573a\u8d44\u8baf · 2026/5/15
• 评级变动
  Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Raises Target Price to $10
  \u5e02\u573a\u8d44\u8baf · 2026/3/14
• 评级变动
  Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $4
  \u5e02\u573a\u8d44\u8baf · 2025/2/22
• 评级变动
  A. G. P. Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $7.5
  \u5e02\u573a\u8d44\u8baf · 2025/11/18
• 评级变动
  Analysts Offer Insights on Healthcare Companies: SELLAS Life Sciences Group (SLS) and Maze Therapeutics, Inc. (MAZE)
  TipRanks · 2025/12/31
• Pre-Market Movement | SLS.US Stock Price Fluctuates Amid Multiple News Items
  \u5e02\u573a\u8d44\u8baf · 2026/6/3
• 评级变动
  Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $7
  \u5e02\u573a\u8d44\u8baf · 2025/12/31
• 评级变动
  A. G. P. Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Raises Target Price to $10
  \u5e02\u573a\u8d44\u8baf · 2026/3/20
• 公司公告
  Syra Health Corp. | 3: Initial statement of beneficial ownership of securities-10% Owner SLS GROUP LLC
  SEC · 2023/9/29
• 评级变动
  A. G. P. Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $10
  \u5e02\u573a\u8d44\u8baf · 2026/5/13
• Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Raises Target Price to $30
  \u5e02\u573a\u8d44\u8baf · 2026/7/9
• A. G. P. Initiates Sellas Life Sciences(SLS.US) With Buy Rating, Announces Target Price $25
  \u5e02\u573a\u8d44\u8baf · 2026/7/6
• Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/8/20
• Earnings Flash (SLS) SELLAS Life Sciences Posts Q2 Loss $0.05, Vs. FactSet Est of $0.05 Loss
  MT Newswires · 2026/8/12

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。